Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding

Blood

Volumn 101, Issue 6, 2003, Pages 2277-2284

  Sun, Yong Hui ^a   Shen, Lei ^a   Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ARGININE; BLOOD CLOTTING FACTOR 5; GLYCINE; PHOSPHOLIPID; PROTEIN C; PROTEIN S; VITAMIN K GROUP;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; EMBRYO; HUMAN; HUMAN CELL; LIGHT SCATTERING; MOLECULAR MECHANICS; MUTAGENESIS; MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WILD TYPE;

EID: 0037443444     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1691     Document Type: Article

References (47)

1. Zwaal RF, Comfurius P, Bevers EM. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta. 1998;1376:433-453.
2. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem. 1988;57:915-956.
3. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988;53:505-518.
4. Nelsestuen GL. Enhancement of vitamin-K-dependent protein function by modification of the γ-carboxyglutamic acid domain: studies of protein C and factor VII. Trends Cardiovasc Med. 1999;9: 162-167.
5. Vermeer C. Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J. 1990;266:625-636.
6. McDonald JF, Shah AM, Schwalbe RA, et al. Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry. 1997;36:5120-5127.
7. Shen L, Shah AM, Dahlbäck B, Nelsestuen GL. Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to proline-10. Biochemistry. 1997;36: 16025-16031.
8. Shen L, Shah AM, Dahlbäck B, Nelsestuen GL. Enhancement of human protein C function by site-directed mutagenesis of the γ-carboxyglutamic acid domain. J Biol Chem. 1998;273: 31086-31091.
9. Shah AM, Kisiel W, Foster DC, Nelsestuen GL. Manipulation of the membrane binding site of vitamin K-dependent proteins: enhanced biological function of human factor VII. Proc Natl Acad Sci U S A. 1998;95:4229-4234.
10. Nicolaes GA, Villoutreix BO, Dahlbäck B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry. 1999;38: 13584-13591.
11. Dahlbäck B. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol. 1997;34:217-234.
12. Esmon CT, Gu JM, Xu J, et al. Regulation and functions of the protein C anticoagulant pathway. Haematologica. 1999;84:363-368.
13. Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem. 1981;256:11128-11131.
14. Yegneswaran S, Wood GM, Esmon CT, Johnson AE. Protein S alters the active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study of topography. J Biol Chem. 1997;272:25013-25021.
15. Yegneswaran S, Smirnov MD, Safa O, et al. Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study. J Biol Chem. 1999;274:5462-5468.
16. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
17. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270:21158-21166.
18. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem. 1995;270:4053-4057.
19. Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270:27852-27858.
20. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem. 1994; 269:18735-18738.
21. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 1994; 369:64-67.
22. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A. 1994;91:1396-1400.
23. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res. 1995;77:1-43.
24. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost. 2001;86:51-56.
25. Rintala E, Seppala OP, Kotilainen P, Pettila V, Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med. 1998;26:965-968.
26. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344:699-709.
27. Dahlbäck B. Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. Biochem J. 1983;209:837-846.
28. Suzuki K, Stenflo J, Dahlbäck B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem. 1983;258:1914-1920.
29. Laurell M, Ikeda K, Lindgren S, Stenflo J. Characterization of monoclonal antibodies against human protein C specific for the calcium ion-induced conformation or for the activation peptide region. FEBS Lett. 1985;191:75-81.
30. Dahlbäck B. Human coagluation factor V purification and thrombin-catalyzed activation. J Clin Invest. 1980;66:583-591.
31. Rosing J, Bakker HM, Thomassen MC, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem. 1993;268:21130-21136.
32. Nelsestuen GL, Lim TK. Equilibria involved in prothrombin- and blood clotting factor X-membrane binding. Biochemistry. 1977;16:4164-4171.
33. Friedrich U, Potzsch B, Preissner KT, Muller-Berghaus G, Ehrlich H. Calcium-dependent activation of protein C by thrombin/thrombomudulin: role of negatively charged amino acids within the activation peptide of protein C. Thromb Haemost. 1994;72:567-572.
34. Dahlbäck B, Lundwall A, Stenflo J. Localization of thrombin cleavage sites in the amino-terminal region of bovine protein S. J Biol Chem. 1986; 261:5111-5115.
35. Norstrom E, Thorelli E, Dahlbäck B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002;100:524-530.
36. Erb EM, Stenflo J, Drakenberg T. Interaction of bovine coagulation factor X and its glutamic-acid-containing fragments with phospholipid membranes. A surface plasmon resonance study. Eur J Biochem. 2002;269:3041-3046.
37. Cooper MA, Hansson A, Lofas S, Williams DH. A vesicle capture sensor chip for kinetic analysis of interactions with membrane-bound receptors. Anal Biochem. 2000;277:196-205.
38. Erb EM, Chen X, Allen S, et al. Characterization of the surfaces generated by liposome binding to the modified dextran matrix of a surface plasmon resonance sensor chip. Anal Biochem. 2000;280: 29-35.
39. Christiansen WT, Jalbert LR, Robertson RM, et al. Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid vesicles. Biochemistry. 1995;34:10376-10382.
40. Seshadri TP, Skrzypczak-Jankun E, Yin M, Tulinsky A. Differences in the metal ion structure between Sr- and Ca-prothrombin fragment 1. Biochemistry. 1994;33:1087-1092.
41. Sunnerhagen M, Forsen S, Hoffren AM, et al. Structure of the Ca(2+)-free Gla domain sheds light on membrane binding of blood coagulation proteins. Nat Struct Biol. 1995;2:504-509.
42. Villoutreix BO, Covell DG, Blom AM, et al. Screening the molecular surface of human anticoagulant protein C: a search for interaction sites. J Comput Aided Mol Des. 2001;15:13-27.
43. Giesen PL, Willems GM, Hemker HC, Hermens WT. Membrane-mediated assembly of the prothrombinase complex. J Biol Chem. 1991;266: 18720-18725.
44. Willems GM, Janssen MP, Salemink I, Wun TC, Lindhout T. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes. Biochemistry. 1998;37:3321-3328.
45. Cutsforth GA, Whitaker RN, Hermans J, Lentz BR. A new model to describe extrinsic protein binding to phospholipid membranes of varying composition: application to human coagulation proteins. Biochemistry. 1989;28:7453-7461.
46. Nelsestuen GL, Kisiel W, Di Scipio RG. Interaction of vitamin K dependent proteins with membranes. Biochemistry. 1978;17:2134-2138.
47. Nesheim ME, Kettner C, Shaw E, Mann KG. Cofactor dependence of factor Xa incorporation into the prothrombinase complex. J Biol Chem. 1981; 256:6537-6540.